Aldeyra Therapeutics Inc   (ALDX)
Other Ticker:  
Price: $3.6600 $0.17 4.871%
Day's High: $3.66 Week Perf: 6.4 %
Day's Low: $ 3.47 30 Day Perf: 20.39 %
Volume (M): 357 52 Wk High: $ 11.97
Volume (M$): $ 1,308 52 Wk Avg: $6.36
Open: $3.48 52 Wk Low: $1.42

 Market Capitalization (Millions $) 216
 Shares Outstanding (Millions) 59
 Employees 152
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -46
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc. is a biotechnology company that aims to develop next-generation therapies for immune-related disorders, including ocular and rare diseases. The company strives to leverage its proprietary technology platform to design and develop novel drug candidates that can effectively target the underlying causes of these conditions.

Founded in 2004, Aldeyra Therapeutics has made significant progress in advancing its drug pipeline using its innovative technologies. The company's research is primarily centered on developing novel approaches to modulate the immune system to treat diseases, such as dry eye syndrome, allergic conjunctivitis, and Sj'gren's syndrome, a rare autoimmune disorder.

Aldeyra Therapeutics focuses on two key areas:

Developing a pipeline of ophthalmic drug candidates: Aldeyra Therapeutics is developing a range of innovative eye drop solutions to treat various eye conditions, including dry eye syndrome and allergic conjunctivitis. The company has designed an innovative approach to target inflammation in the eye, which is the underlying cause of many eye-related diseases.

Developing a pipeline of drug candidates for rare and immune-mediated diseases: Aldeyra Therapeutics is developing a range of biologic and small molecule therapies to target rare and immune-mediated diseases. The company's lead candidate, ADX-102, is a small-molecule inhibitor that targets inflammation and can potentially treat Sj'gren's syndrome.

The company's drug development pipeline comprises several compounds in various stages of development, including pre-clinical and clinical stages. Aldeyra Therapeutics has a team of experienced drug development professionals, including scientists, medical professionals, and clinicians.

Aldeyra Therapeutics has also secured several partnerships with leading pharmaceutical companies to advance its drug development programs. The company has partnered with Janssen Pharmaceutica and LG Life Sciences to develop its drug candidates for ocular diseases.

In conclusion, Aldeyra Therapeutics is a promising biotech company that is using innovative technologies to develop novel therapies for immune-related disorders. With a strong pipeline of drug candidates in development and strategic partnerships with leading pharmaceutical companies, the company is poised for significant growth and success in the biotech industry.

   Company Address: 131 Hartwell Avenue Lexington 2421 MA
   Company Phone Number: 761-4904   Stock Exchange / Ticker: NASDAQ ALDX
   ALDX is expected to report next financial results on March 08, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc Records a Surprising Operating Loss of $-9.55 Million in Latest Fiscal Period

Aldeyra Therapeutics Inc., a major pharmaceutical preparations company, recently reported its financial performance for the earnings season of July to September 30, 2023. While the stockholders did not anticipate any major changes in the business, they were pleased to see a significant improvement in the company's operating loss compared to the same period in the previous year.
During the July to September 2023 period, Aldeyra Therapeutics Inc. recorded an operating loss of $-9.55037 million, which is considerably lower than the operating loss of $-14.784556 million in the third quarter of 2022. This reduction in operating loss is an important indicator of the company's progress.

Aldeyra Therapeutics Inc

Remarkable Progress: Aldeyra Therapeutics Inc Trims Operating Loss to $-17.7 Million in Q2 2023 at ALDX

In the latest financial reporting cycle, Aldeyra Therapeutics Inc. (ALDX) has surprised investors with some noteworthy adjustments in its revenue. Contrary to expectations, the company's operating loss during the April to June 2023 period stands at $-10.342657 million, which may seem like bad news on the surface. However, when compared to the corresponding period a year ago, where the operating loss was $-17.714934 million, it becomes apparent that Aldeyra Therapeutics Inc. is making significant progress. This notable improvement in financial performance is expected to provide assurance to countless investors.
Positive Outlook
Developing a business model in the pharmaceutical industry can be challenging, but Aldeyra Therapeutics Inc. seems to be on the right track. The company has successfully reduced its diminishing returns, which were at $-17.781 million in the second quarter of 2022, to $-8.987 million in the fiscal period ending June 30, 2023. This improvement indicates that the company's strategies and initiatives are yielding positive outcomes.

Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc's First Quarter of 2023 Sees Accelerating Expenses2.

Investors looking for a bearish pharmaceutical stock to sell short should consider Aldeyra Therapeutics Inc (ALDX), a company that has been running at a cumulative net loss of $-61 million for the past year ending in the first quarter of 2023.
This poor financial performance has led to a negative return on equity (ROE) of -38.98%, which is in stark contrast to 37 other companies in the Major Pharmaceutical Preparations industry that have posted a higher ROE. In fact, ALDX's overall ranking has only improved slightly in the first quarter of 2023 to a rank of 1120, up from a dismal rank of 3274 in the fourth quarter of 2022.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com